Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444606) titled 'Dose Ranging, Toxicity Seeking, Phase 1 Trial of Oncolytic Adenoviral Therapy for Melanoma Intracranial and Extracranial Metastases' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: Non-Randomized. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Melanoma
Intervention:
Drug: DNX-2401
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 31, 2026
Target Sample Size: 50
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials....